American Diabetes Association

Table 2—

Baseline levels and changes from baseline (negative values correspond to improvement) in the TSS and its individual subscores after 5 weeks of treatment (last value carried forward)

	Placebo	ALA600	ALA1200	ALA1800
TSS
Baseline	9.27 ± 1.56	9.44 ± 1.86	9.40 ± 1.64	9.02 ± 1.61
Change	−2.92 ± 3.18	−4.85 ± 3.03^*	−4.50 ± 3.28^*	−4.70 ± 3.54^*
Stabbing pain
Baseline	2.21 ± 0.77	2.32 ± 0.94	2.38 ± 0.89	2.03 ± 0.88
Change	−0.83 ± 1.14	−1.40 ± 1.15^*	−1.56 ± 1.07^*	−1.46 ± 1.20^*
Burning pain
Baseline	2.11 ± 0.87	2.21 ± 1.07	2.17 ± 1.05	2.15 ± 1.03
Change	−0.50 ± 1.15	−1.32 ± 1.07^*	−1.09 ± 1.19^*	−1.15 ± 1.41^*
Paresthesia
Baseline	2.21 ± 0.63	2.32 ± 0.80	2.12 ± 0.80	2.17 ± 0.69
Change	−0.80 ± 1.17	−1.16 ± 1.26	−0.85 ± 1.21	−1.12 ± 1.20
Numbness
Baseline	2.74 ± 0.67	2.58 ± 0.67	2.73 ± 0.66	2.67 ± 0.72
Change	−0.79 ± 1.09	−0.97 ± 1.06	−0.99 ± 1.13	−0.98 ± 1.16

	Placebo	ALA600	ALA1200	ALA1800
TSS
Baseline	9.27 ± 1.56	9.44 ± 1.86	9.40 ± 1.64	9.02 ± 1.61
Change	−2.92 ± 3.18	−4.85 ± 3.03^*	−4.50 ± 3.28^*	−4.70 ± 3.54^*
Stabbing pain
Baseline	2.21 ± 0.77	2.32 ± 0.94	2.38 ± 0.89	2.03 ± 0.88
Change	−0.83 ± 1.14	−1.40 ± 1.15^*	−1.56 ± 1.07^*	−1.46 ± 1.20^*
Burning pain
Baseline	2.11 ± 0.87	2.21 ± 1.07	2.17 ± 1.05	2.15 ± 1.03
Change	−0.50 ± 1.15	−1.32 ± 1.07^*	−1.09 ± 1.19^*	−1.15 ± 1.41^*
Paresthesia
Baseline	2.21 ± 0.63	2.32 ± 0.80	2.12 ± 0.80	2.17 ± 0.69
Change	−0.80 ± 1.17	−1.16 ± 1.26	−0.85 ± 1.21	−1.12 ± 1.20
Numbness
Baseline	2.74 ± 0.67	2.58 ± 0.67	2.73 ± 0.66	2.67 ± 0.72
Change	−0.79 ± 1.09	−0.97 ± 1.06	−0.99 ± 1.13	−0.98 ± 1.16

Data are means ± SD.

*

P < 0.05 vs. placebo.